Shares of Novo Nordisk NVO were unchanged after the company reported Q4 results.
Quarterly Results
Earnings per share rose 14.29% year over year to $0.64, which were in line with the estimate of $0.64.
Revenue of $5,142,000,000 up by 5.74% year over year, which missed the estimate of $5,350,000,000.
Looking Ahead
Novo Nordisk hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Feb 03, 2021
Time: 07:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/oeqkkcyq
Price Action
52-week high: $73.92
Company's 52-week low was at $49.24
Price action over last quarter: Up 9.13%
Company Profile
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
